Climate Influence on Physiotherapy in Multiple Sclerosis

NCT ID: NCT01057719

Last Updated: 2010-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study was to compare the effect of inpatient physiotherapy in a warm climate versus physiotherapy in a colder climate in multiple sclerosis (MS), in both short- and long term perspectives.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Empirically, several patients with MS have reported improved function in warm climate during therapy or vacation. This is in contrast to the heat intolerance frequently reported in MS. Heat intolerance seems, however, to be individually distributed among the MS patients, and may seem to be related to the degree of warmth.

Sixty patients with gait problems and without heat intolerance were included in a cross-over study. They were randomized to a 4-week inpatient physiotherapy based on the Bobath concept in Norway or Spain, with cross-over the year after. Data from five physical performance measures and six self-reported measures were collected at screening, baseline, after treatment and three and six months after both treatment-periods. Change over time within groups and comparisons of change between groups were analyzed by mixed models.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Physiotherapy in Spain

Daily inpatient physiotherapy for four weeks in a warm climate

Group Type EXPERIMENTAL

Physiotherapy

Intervention Type OTHER

Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks

Physiotherapy in Norway

Daily inpatient physiotherapy for four weeks in a cold climate

Group Type EXPERIMENTAL

Physiotherapy

Intervention Type OTHER

Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Physiotherapy

Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Physical Therapy Subtropical climate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between 18 and 60 years of age (both included).
* Multiple sclerosis according to the McDonald criteria
* Disability equivalent to Expanded Disability Status Score (EDSS) between 4.0 and 6.5 (both included)
* Prepared to and considered able to follow the protocol and to attend the planned visits during the whole study period.
* Given written informed consent

Exclusion Criteria

* An active MS (attack or progression) during one month prior to inclusion or start of treatment.
* Received treatment with glucocorticoids the last month prior to inclusion or start of treatment.
* Excessive fatigue or severe cognitive dysfunction related to MS that would preclude safe participation in the protocol.
* Suffered from major depression or any other psychiatric disorder that would preclude safe participation in the protocol.
* Heat intolerance.
* Other serious concomitant disease that could preclude safe participation in the protocol.
* Alcohol or drug abuse or consumption that could preclude participation according to the protocol and to attend the planned visits during the whole study period.
* Breastfeeding or pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oslo University Hospital

OTHER

Sponsor Role collaborator

University Hospital, Akershus

OTHER

Sponsor Role collaborator

University of Bergen

OTHER

Sponsor Role collaborator

Haukeland University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Haukeland University Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tori Smedal, MSc

Role: PRINCIPAL_INVESTIGATOR

Haukeland University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Haukeland University Hospital

Bergen, , Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

012.06

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.